top of page
  • Writer's pictureSL

ME/CFS- Lifting the Fog!

Fighting Myalgic Encephalomyelitis/Chronic Fatigue

Despite Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) affecting millions worldwide, few have the knowledge to appropriately diagnose or manage this debilitating condition. Unfortunately, clinical guidance has been scarce, and in some cases suffers spend years searching for a diagnosis. We know that more than 90% of Australian sufferers remain undiagnosed, and those diagnosed often receive inappropriate treatment. This is of significant importance, because after acute COVID-19, a significant percentage of sufferers remain ill for many months with an illness similar to ME/CFS.

There are many steps we can take to improve the health, function, and quality of life of

those with ME/CFS, including those who develop ME/CFS after COVID-19 infection. Patients with lingering illness following acute COVID-19 who do not fully meet criteria for ME/CFS may also benefit from these approaches.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a chronic, multi-system disease affecting millions worldwide. Post Covid-19 infection, we are seeing an increase in presentations of patients with ME/CFS.

Despite its high prevalence and disabling nature, medical education programs rarely

cover ME/CFS and guidance for practicing clinicians is often outdated and inappropriate.

With over 20 years’ experience treating ME/CFS, Elixir’s specialists are going to unpack this condition, its cause and the latest in treatment protocols.

Over the next few weeks, the team at Elixir Compounding Pharmacy will publish a special blog on fighting ME/CFS. If you or a loved one is struggling with chronic fatigue, be sure to tune in!

2 views0 comments


bottom of page